Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Rezpegaldesleukin (NKTR-358) in Atopic dermatitis. The expected timing is based on the latest available company guidance and may change.
REZOLVE-AD trial. 11/2023- Trial initiated. 1/10/25- Target enrollment reached. 6/24/25- Ph2b met primary & secondary endpoints. 9/18/25- Presented results at EADV'25. 11/8/25- Presentation at ACAAI'25. Report 52wk data in Q1 2026. 11/06/25:- Company highlighted emerging REZOLVE-AD Ph2b data and upcoming late-breaking oral presentation at ACAAI 2025 showing efficacy in atopic dermatitis and co-morbid asthma; 52-week data remain planned for Q1 2026. 02/09/26:- Company to host Feb 10, 2026 webcast for 36-week REZOLVE-AD Ph2b topline results. 03/12/26:- Early 2026 52-week REZOLVE-AD data reported; Ph3 AD to start Q2 2026; future maintenance/off-treatment readouts planned. 03/20/26:- REZOLVE-AD Ph2b efficacy and safety data to be presented at AAD 2026 on March 28, 2026. 03/28/26:- REZOLVE-AD AAD 2026 data presented. Phase 3 ZENITH-AD planned for Q2 2026. 05/07/26:- ZENITH-AD Ph3 in atopic dermatitis to initiate by July 2026; off-treatment REZOLVE-AD data expected Q1 2027. 07/21/26:- ZENITH AD-1/2 Ph3 started; AD-3 starts Sep 2026. Initial topline Mid-2028; BLA 2029. 08/13/26:- ZENITH AD-1 and AD-2 Phase 3 trials were initiated. REZOLVE-AD maintenance data will be presented October 1, 2026. Initial Phase 3 data remain expected Mid-2028; BLA submission is planned for 2029.
Verification
Confirm timing and program details against the company announcement or filing.